Jeehee Yoon

Jul 24, 2023 | frontiersin.org | Angela Lombardi |Hanna Lee |Pasquale Mone |Jeehee Yoon

IntroductionImmunotherapy has revolutionized the treatment of many cancer types (1). Immune checkpoint inhibitors (ICIs) target the cytotoxic T lymphocyte antigen 4 (CTLA-4)/CD28/programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis, leading to immune activation in the tumor microenvironment (2, 3).